查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493216

大麻药品市场规模、份额、趋势分析报告：按品牌类型、地区、细分市场预测，2024-2030 年

Cannabis Pharmaceuticals Market Size, Share & Trends Analysis Report By Brand Type (Sativex, Epidiolex, Other Brands), By Region (North America, Middle East And Africa, Asia Pacific, Europe), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

大麻药品市场成长与趋势：

Grand View Research, Inc. 的一项新研究显示，到 2030 年，全球大麻药品市场规模预计将达到 1,024 亿美元，2024 年至 2030 年复合年增长率为 53.3%。

大麻在各种医疗应用中的使用不断增加正在推动全球大麻药物市场的成长。例如，大麻被广泛用于治疗患有帕金森氏症、癌症、关节炎和阿兹海默症慢性疾病以及忧郁症、焦虑症和癫痫症等神经系统问题的患者。此外，慢性疼痛和疼痛管理疗法的疾病负担正在增加。因此，有效缓解疼痛的大麻产品的消费量正在增加。

近年来，由于医疗用途的全球接受度和合法化程度的提高，市场发生了重大变化。这一发展导致大麻药物专利申请显着增加。例如，2023年10月，专注于创造中枢神经神经病变和罕见疾病治疗方法的临床阶段专业製药公司SciSparc Ltd.提交了大麻素和N-酰基乙醇胺组合的专利申请（以下简称「我们」）。该专利已正式受理。该专利由澳洲智慧财产局授予，该机构是负责管理智慧财产权和专利法的澳洲政府机构。接受此类专利对于促进创新、帮助企业保护其发明以及鼓励进一步的研究和开发至关重要。随着大麻素的药用价值得到广泛认可，并且有可能为世界各地的患者提供新的治疗选择，这一趋势预计将持续下去。

此外，大麻产业的各个公司和研究机构正在进行研究，以检验与 CBD 产品相关的声明，这正在推动市场成长。为了满足不断增长的消费者需求而采用创新产品进一步支持了这一趋势。根据美国食品药物管理局(FDA) 2023 年 2 月发表的一项研究，FDA 推荐 Epidiolex（一种大麻二酚 (CBD) 的精製形式）用于治疗患有肠漏症候群或Dravet 综合征的2 岁以下患者的癫痫发作年龄及以上核准。 FDA 也批准 Marinol 和 Syndros 在美国用于医疗用途。这些药物已被核准用于改善癌症化疗引起的噁心，并控制可能导致爱滋病患者体重减轻的厌食症。 2021 年 11 月，科罗拉多州立大学成立了一个专注于 CBD 的新研究中心。同月，Greenrise Global Brands, Inc. 的子公司 AMP Alternative Medical Products GmbH 在德国市场推出了屈大麻酚产品。

此外，公司正在实施多样化的策略来增加其在市场上的影响力。例如，2024 年 3 月，製药业大麻素领域的 Brains Bioceuticals（也固体Brains Bio）宣布全球首次生产用作活性药物成分（API）的四氢大麻酚（THC）。结果。 2021年11月，生物製药公司Avicana与一家知名的阿根廷製药公司签署了智慧财产权（IP）和分销协议。作为该协议的一部分，Avicanna 将授予其专有的 10% CBD 药物配方非独家许可。

大麻药品市场报告亮点

  • 按品牌类型划分，由于医疗保健专业人员和患者对药用大麻的需求很高，Epidiolex 细分市场在 2023 年占据了销售份额。
  • 2023年，由于大麻消费量增加、对大麻及其产品的认识和积极态度不断增强，欧洲以41.9%的收益占有率主导整个市场。北美是最早将医疗和娱乐大麻使用合法化的地区之一。
  • 该领域的一些主要企业包括 Jazz Pharmaceuticals, Inc.、AbbVie, Inc.、Insys Therapeutics, Inc. 和 Bausch Health Companies, Inc.。

目录

第一章 大麻药品市场：调查方法与范围

第二章 大麻药品市场：执行概述

  • 市场展望
  • 分部展望
  • 竞争考察

第三章 大麻药品市场：变数、趋势、范围

  • 市场体系展望
  • 市场动态
  • 大麻药品市场分析工具

第四章 大麻药品市场：品牌类型、估计与趋势分析

  • 2023年及2030年品牌类型市场占有率
  • 细分仪表板
  • 按品牌类型分類的全球大麻药品市场展望
  • 2018-2030年市场规模、预测及趋势分析

第五章 大麻药品市场：区域估计与趋势分析

  • 2023 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 按地区分類的全球市场概述
  • 2018-2030年市场规模、预测及趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 荷兰
    • 义大利
    • 西班牙
    • 克罗埃西亚
    • 波兰
    • 捷克共和国
    • 瑞士
  • 亚太地区
    • 日本
    • 澳洲
    • 纽西兰
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 乌拉圭
    • 智利
    • 秘鲁
  • 中东/非洲
    • 南非
    • 以色列

第六章 竞争状况

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 2023年主要企业市场占有率分析
    • Canopy Growth Corporation
    • Jazz Pharmaceuticals, Inc.
    • AbbVie, Inc.
    • Insys Therapeutics, Inc.
    • Bausch Health Companies, Inc.
Product Code: GVR-4-68038-473-4

Cannabis Pharmaceuticals Market Growth & Trends:

The global cannabis pharmaceuticals market size is expected to reach USD 102.4 billion by 2030, expanding at a CAGR of 53.3% from 2024 to 2030, according to a new study by Grand View Research, Inc. Growing use of cannabis in various medical applications is driving the global pharmaceutical cannabis market growth. For instance, cannabis is widely used for treating patients suffering from chronic conditions, such as Parkinson's disease, cancer, arthritis, and Alzheimer's disease, as well as neurologic problems, such as depression, anxiety, & epilepsy. Moreover, there is a growing disease burden of chronic pain and pain management therapies. This, in turn, is increasing cannabis product consumption as it is effective in pain management.

The market has undergone substantial changes in recent years, driven by increased global acceptance and legalization for medical use. This development has led to a notable rise in patent applications for cannabis-based pharmaceuticals. For instance, in October 2023, SciSparc Ltd., a specialized clinical-stage pharmaceutical company focusing on creating treatments for central nervous system disorders and rare diseases, announced that its patent application for the Combinations of Cannabinoids and N-Acylethanolamines (the "Patent") had been officially accepted. The patent was awarded by IP Australia, the Australian government agency responsible for managing intellectual property rights and patent legislation. Accepting such patents is vital for promoting innovation, allowing companies to safeguard their inventions and stimulate further research and development. This trend is expected to persist as the medicinal benefits of cannabinoids gain wider acknowledgment, potentially offering new treatment options for patients worldwide.

Furthermore, various companies and research institutes in the cannabis industry are conducting research studies to validate claims associated with CBD products, which is fueling market growth. This trend is further supported by the introduction of innovative products to meet the increasing consumer demand. According to the U.S. Food and Drug Administration (FDA) study published in February 2023, the FDA has given its approval to Epidiolex, a medication that contains a refined version of cannabidiol (CBD), for the treatment of seizures linked to Lennox-Gastaut syndrome or Dravet syndrome in patients aged 2 years and above. The FDA has also authorized the use of Marinol and Syndros for medical purposes in the U.S. These medications are approved for improving nausea caused by cancer chemotherapy and for managing anorexia leading to weight loss in patients with AIDS. In November 2021, Colorado State University inaugurated a new research center dedicated to CBD. Similarly, in the same month, AMP Alternative Medical Products GmbH, a subsidiary of Greenrise Global Brands, Inc., launched a Dronabinol product in the German market.

Moreover, companies are implementing diverse strategies to enhance their market presence. For instance, in March 2024, Brains Bioceutical Corp, also known as Brains Bio, a company in the pharmaceutical industry's cannabinoid sector, revealed its achievement in developing the world's first solid form of Tetrahydrocannabinol (THC) for use as an Active Pharmaceutical Ingredient (API). In November 2021, Avicanna, a biopharmaceutical firm, finalized an intellectual property (IP) and distribution agreement with a well-established pharmaceutical company in Argentina. As part of this agreement, Avicanna is expected to grant a nonexclusive license for its proprietary 10% CBD pharmaceutical drug preparation.

Cannabis Pharmaceuticals Market Report Highlights:

  • Based on brand type, Epidiolex segment accounted for the revenue share in 2023 owing to the high demand among healthcare practitioners and patients for medicinal cannabis
  • In 2023, Europe dominated the overall market with a revenue share of 41.9% owing to increasing cannabis consumption, as well as rising awareness and positive attitude towards cannabis and its products. North America was among the first regions to legalize the use of medical and recreational cannabis.
  • Some of the major players operating in this space are Jazz Pharmaceuticals, Inc., AbbVie, Inc., Insys Therapeutics, Inc., Bausch Health Companies, Inc.

Table of Contents

Chapter 1. Cannabis Pharmaceuticals Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Brand Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Cannabis Pharmaceuticals Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Brand type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cannabis Pharmaceuticals Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cannabis Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cannabis Pharmaceuticals Market: Brand Type Estimates & Trend Analysis

  • 4.1. Brand Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cannabis Pharmaceuticals Market by Brand Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Sativex
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Epidiolex
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Brands
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cannabis Pharmaceuticals Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. France
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Netherlands
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework/ reimbursement structure
      • 5.6.4.3. Competitive scenario
      • 5.6.4.4. Netherlands market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. Italy
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework/ reimbursement structure
      • 5.6.5.3. Competitive scenario
      • 5.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Spain
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework/ reimbursement structure
      • 5.6.6.3. Competitive scenario
      • 5.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.7. Croatia
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework/ reimbursement structure
      • 5.6.7.3. Competitive scenario
      • 5.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.8. Poland
      • 5.6.8.1. Key country dynamics
      • 5.6.8.2. Regulatory framework/ reimbursement structure
      • 5.6.8.3. Competitive scenario
      • 5.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.9. Czech Republic
      • 5.6.9.1. Key country dynamics
      • 5.6.9.2. Regulatory framework/ reimbursement structure
      • 5.6.9.3. Competitive scenario
      • 5.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.10. Switzerland
      • 5.6.10.1. Key country dynamics
      • 5.6.10.2. Regulatory framework/ reimbursement structure
      • 5.6.10.3. Competitive scenario
      • 5.6.10.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Australia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. New Zealand
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework/ reimbursement structure
      • 5.8.1.3. Competitive scenario
      • 5.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework/ reimbursement structure
      • 5.8.2.3. Competitive scenario
      • 5.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework/ reimbursement structure
      • 5.8.3.3. Competitive scenario
      • 5.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Colombia
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework/ reimbursement structure
      • 5.8.4.3. Competitive scenario
      • 5.8.4.4. Colombia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.5. Uruguay
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Regulatory framework/ reimbursement structure
      • 5.8.5.3. Competitive scenario
      • 5.8.5.4. Uruguay market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.6. Chile
      • 5.8.6.1. Key country dynamics
      • 5.8.6.2. Regulatory framework/ reimbursement structure
      • 5.8.6.3. Competitive scenario
      • 5.8.6.4. Chile market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.7. Peru
      • 5.8.7.1. Key country dynamics
      • 5.8.7.2. Regulatory framework/ reimbursement structure
      • 5.8.7.3. Competitive scenario
      • 5.8.7.4. Peru market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. South Africa
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Regulatory framework/ reimbursement structure
      • 5.9.1.3. Competitive scenario
      • 5.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.9.2. Isarel
      • 5.9.2.1. Key country dynamics
      • 5.9.2.2. Regulatory framework/ reimbursement structure
      • 5.9.2.3. Competitive scenario
      • 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2023
    • 6.3.4. Canopy Growth Corporation
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Jazz Pharmaceuticals, Inc.
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. AbbVie, Inc.
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Insys Therapeutics, Inc.
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Bausch Health Companies, Inc.
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America cannabis pharmaceuticals market, 2018 - 2030 (USD Million)
  • Table 3 North America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 5 Canada cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 6 Europe cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 7 Europe cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 8 Germany cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 9 UK cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 10 Netherlands cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 11 France cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 12 Italy cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 13 Spain cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 14 Croatia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 15 Poland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 16 Czech Republic cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 17 Switzerland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 20 Japan cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 21 New Zealand cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 22 Australia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 23 South Korea cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 24 Latin America cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 25 Latin America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 26 Brazil cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 27 Argentina cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 28 Mexico cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 29 Uruguay cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 30 Colombia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 31 Chile cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 32 Peru cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 33 MEA cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 34 MEA cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 35 South Africa cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 36 Israel cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cannabis pharmaceuticals market: market outlook
  • Fig. 9 Cannabis pharmaceuticals competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Cannabis pharmaceuticals market driver impact
  • Fig. 15 Cannabis pharmaceuticals market restraint impact
  • Fig. 16 Cannabis pharmaceuticals market strategic initiatives analysis
  • Fig. 17 Cannabis pharmaceuticals market: Brand type movement analysis
  • Fig. 18 Cannabis pharmaceuticals market: Brand type outlook and key takeaways
  • Fig. 19 Sativex market estimates and forecast, 2018 - 2030
  • Fig. 20 Epidiolex market estimates and forecast, 2018 - 2030
  • Fig. 21 Other brands market estimates and forecast, 2018 - 2030
  • Fig. 22 Global Cannabis pharmaceuticals market: Regional movement analysis
  • Fig. 23 Global Cannabis pharmaceuticals market: Regional outlook and key takeaways
  • Fig. 24 Global Cannabis pharmaceuticals market share and leading players
  • Fig. 25 North America market share and leading players
  • Fig. 26 Europe market share and leading players
  • Fig. 27 Asia Pacific market share and leading players
  • Fig. 28 Latin America market share and leading players
  • Fig. 29 Middle East & Africa market share and leading players
  • Fig. 30 North America, by country
  • Fig. 31 North America
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030
  • Fig. 33 U.S.
  • Fig. 34 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 35 Canada
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 37 Europe
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 39 UK
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany
  • Fig. 42 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 43 Netherlands
  • Fig. 44 Netherlands market estimates and forecasts, 2018 - 2030
  • Fig. 45 France
  • Fig. 46 France market estimates and forecasts, 2018 - 2030
  • Fig. 47 Italy
  • Fig. 48 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 49 Spain
  • Fig. 50 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 51 Croatia
  • Fig. 52 Croatia market estimates and forecasts, 2018 - 2030
  • Fig. 53 Poland
  • Fig. 54 Poland market estimates and forecasts, 2018 - 2030
  • Fig. 55 Czech Republic
  • Fig. 56 Czech Republic market estimates and forecasts, 2018 - 2030
  • Fig. 57 Switzerland
  • Fig. 58 Switzerland market estimates and forecasts, 2018 - 2030
  • Fig. 59 Asia Pacific
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 61 Japan
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 63 South Korea
  • Fig. 64 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 65 New Zealand
  • Fig. 66 New Zealand market estimates and forecasts, 2018 - 2030
  • Fig. 67 Australia
  • Fig. 68 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 69 Latin America
  • Fig. 70 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 71 Brazil
  • Fig. 72 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 73 Mexico
  • Fig. 74 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 75 Argentina
  • Fig. 76 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 77 Colombia
  • Fig. 78 Colombia market estimates and forecasts, 2018 - 2030
  • Fig. 79 Uruguay
  • Fig. 80 Uruguay market estimates and forecasts, 2018 - 2030
  • Fig. 81 Chile
  • Fig. 82 Chile market estimates and forecasts, 2018 - 2030
  • Fig. 83 Peru
  • Fig. 84 Peru market estimates and forecasts, 2018 - 2030
  • Fig. 85 Middle East and Africa
  • Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Africa
  • Fig. 88 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 89 Israel
  • Fig. 90 Israel Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Market position analysis of key market players - Cannabis pharmaceuticals market